{"id":5211,"date":"2021-10-06T15:00:00","date_gmt":"2021-10-06T19:00:00","guid":{"rendered":"https:\/\/bridgebioprod.wpengine.com\/?p=5211"},"modified":"2022-06-23T11:41:01","modified_gmt":"2022-06-23T15:41:01","slug":"bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/","title":{"rendered":"BridgeBio Pharma to Host Virtual R&#038;D Day on October 12, 2021"},"content":{"rendered":"\r\n<p>PALO ALTO, CA\u00a0\u2013 October 6, 2021 \u2013 BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, today announced that it will host its second R&amp;D Day on Tuesday, October 12, 2021, at 8:30 a.m. ET.<\/p>\r\n\r\n\r\n\r\n<p>BridgeBio founder and CEO Neil Kumar, Ph.D., will present and be joined by Richard Scheller, Ph.D., chairman of R&amp;D at BridgeBio; Charles Homcy, M.D., chairman of pharmaceuticals at BridgeBio; and Uma Sinha, Ph.D., chief scientific officer at BridgeBio, along with senior scientists and physicians leading BridgeBio\u2019s drug discovery and development programs. BridgeBio has 14 programs that are being advanced in the clinic or commercial setting with 30+ programs total in its pipeline for patients living with genetic diseases and genetically-driven cancers.<\/p>\r\n\r\n\r\n\r\n<p>BridgeBio will unveil new programs, share new information about its pipeline and discuss how it is broadening the scope of its R&amp;D engine. It will also cover the company\u2019s most significant near-term catalysts with a focus on the upcoming topline results for acoramidis, BridgeBio\u2019s investigational therapy for transthyretin (TTR) amyloidosis (ATTR). ATTR is a rare heart condition with a progressive and debilitating impact on quality of life likely affecting more than 400,000 patients worldwide.<\/p>\r\n\r\n\r\n\r\n<p>Topline results from Part A are expected in late 2021 and from Part B in 2023. The primary endpoint at Part A is the change from baseline in a 6-minute walk distance (6MWD) in trial participants receiving acoramidis or placebo after 12 months. If the change from baseline in 6MWD in Part A is highly statistically significant, BridgeBio expects to submit an application for regulatory approval of acoramidis in 2022 to the U.S. Food and Drug Administration.<\/p>\r\n\r\n\r\n\r\n<p>The R&amp;D Day program importantly and additionally will highlight BridgeBio\u2019s broader efforts in cardiorenal, progress in its KRAS portfolio, and advancements in its previously disclosed early-stage Mendelian programs. The Company will also be unveiling new programs in gene therapy.<\/p>\r\n\r\n\r\n\r\n<p><strong><u>Agenda:<\/u><\/strong><\/p>\r\n\r\n\r\n\r\n<ul class=\"wp-block-list\">\r\n<li><strong>Welcome and introduction \u2013<\/strong> Grace Rauh, vice president of marketing and communications, BridgeBio Pharma<\/li>\r\n<li><strong>Genetic basis of disease \u2013<\/strong> Richard Scheller, Ph.D., chairman of R&amp;D, BridgeBio Pharma<\/li>\r\n<li><strong>BridgeBio\u2019s endless summer \u2013<\/strong> Neil Kumar, Ph.D., founder and CEO, BridgeBio Pharma<\/li>\r\n<li><strong>Precision cardiorenal introduction \u2013<\/strong> Cameron Turtle, D.Phil., chief strategy officer, BridgeBio Pharma<\/li>\r\n<li><strong>Acoramidis: TTR stabilizer for ATTR \u2013<\/strong> Jonathan Fox, M.D., Ph.D., chief medical officer, BridgeBio Cardiorenal<\/li>\r\n<li><strong>Encaleret: Calcium sensing receptor (CaSR) inhibitor for autosomal dominant hypocalcemia type 1 (ADH1) \u2013<\/strong> Mary Scott Roberts, M.D., senior director of clinical development, BridgeBio Cardiorenal<\/li>\r\n<li><strong>Gene therapy platform \u2013<\/strong> Eric David, M.D., J.D., CEO, BridgeBio Gene Therapy<\/li>\r\n<li><strong>Mendelian programs: Primary hyperoxaluria type 1 (PH1), limb-girdle muscular dystrophy type 2i (LGMD2i), recessive dystrophic epidermolysis bullosa (rDEB) \u2013<\/strong> Uma Sinha, Ph.D., chief scientific officer, BridgeBio Pharma<\/li>\r\n<li><strong>Precision oncology programs: KRAS, SHP2 \u2013<\/strong> Eli Wallace, Ph.D., chief scientific officer, BridgeBio Oncology<\/li>\r\n<li><strong>BridgeBioX \u2013<\/strong> Charles Homcy, M.D., chairman of pharmaceuticals, BridgeBio Pharma<\/li>\r\n<li><strong>Q&amp;A<\/strong><\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<p>The event will be webcast, with a link available in the event calendar on BridgeBio\u2019s investor website,\u00a0<a href=\"https:\/\/investor.bridgebiodev.wpengine.com\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>https:\/\/investor.bridgebiodev.wpengine.com\/<\/strong><\/a>. A replay of the webcast will be available for one year following the event.<\/p>\r\n\r\n\r\n\r\n<p>To register for BridgeBio\u2019s R&amp;D Day, please sign up\u00a0<a href=\"https:\/\/wsw.com\/webcast\/cc\/bbio2\/register.aspx?conf=cc&amp;page=bbio2&amp;url=https:\/\/wsw.com\/webcast\/cc\/bbio2\/1408212\">here<\/a>.\u00a0To view the agenda and speaker profiles visit our R&amp;D Day\u00a0<a href=\"https:\/\/wsw.com\/webcast\/cc\/bbio2\/1408212\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>webpage<\/strong><\/a>. Attendees must register and watch the webcast to participate in the Q&amp;A sessions.<\/p>\r\n\r\n\r\n\r\n<p><strong>About BridgeBio Pharma, Inc.<\/strong><\/p>\r\n\r\n\r\n\r\n<p>BridgeBio Pharma, Inc. (BridgeBio) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the company\u2019s two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit <a href=\"http:\/\/bridgebio.com\/\">bridgebiodev.wpengine.com<\/a> and follow us on <a href=\"https:\/\/www.linkedin.com\/company\/bridgebio\/\" target=\"_blank\" rel=\"noreferrer noopener\">LinkedIn<\/a> and <a href=\"https:\/\/twitter.com\/BridgeBioPharma\" target=\"_blank\" rel=\"noreferrer noopener\">Twitter<\/a>.<\/p>\r\n\r\n\r\n\r\n<p><strong>BridgeBio Media Contact:<\/strong><br \/>Grace Rauh<br \/><a href=\"mailto:Grace.rauh@bridgebiodev.wpengine.com\">Grace.rauh@bridgebiodev.wpengine.com<\/a><br \/>(917) 232-5478<\/p>\r\n\r\n\r\n\r\n<p><strong>BridgeBio Investor Contact:<\/strong><br \/>Katherine Yau<br \/><a href=\"mailto:katherine.yau@bridgebiodev.wpengine.com\" target=\"_blank\" rel=\"noreferrer noopener\">katherine.yau@bridgebiodev.wpengine.com<\/a><br \/>(516) 554-5989<\/p>\r\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, CA\u00a0\u2013 October 6, 2021 \u2013 BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, today announced that it will host its second R&amp;D Day on Tuesday, October 12, 2021, at 8:30 a.m. ET. BridgeBio founder and CEO Neil Kumar, Ph.D., will present and be joined by [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[10],"tags":[],"class_list":["post-5211","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":{"people":false,"external_link":"","presentation":"","meta_short_title":"BridgeBio to Host Virtual R&D Day on October 12, 2021","meta_description":"BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021","meta_share_image":false},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio Pharma to Host Virtual R&amp;D Day on October 12, 2021 | BridgeBio<\/title>\n<meta name=\"description\" content=\"BridgeBio announced that it will host its second R&amp;D Day on Tuesday, October 12, 2021, at 8:30 a.m. ET. Learn more today!\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio Pharma to Host Virtual R&amp;D Day on October 12, 2021 | BridgeBio\" \/>\n<meta property=\"og:description\" content=\"BridgeBio announced that it will host its second R&amp;D Day on Tuesday, October 12, 2021, at 8:30 a.m. ET. Learn more today!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-06T19:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-23T15:41:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Cybele Gouverneur\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Cybele Gouverneur\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/\",\"name\":\"BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021 | BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2021-10-06T19:00:00+00:00\",\"dateModified\":\"2022-06-23T15:41:01+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7\"},\"description\":\"BridgeBio announced that it will host its second R&D Day on Tuesday, October 12, 2021, at 8:30 a.m. ET. Learn more today!\",\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma to Host Virtual R&#038;D Day on October 12, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7\",\"name\":\"Cybele Gouverneur\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g\",\"caption\":\"Cybele Gouverneur\"},\"url\":\"https:\/\/bridgebio.com\/author\/cybele-gouverneur\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021 | BridgeBio","description":"BridgeBio announced that it will host its second R&D Day on Tuesday, October 12, 2021, at 8:30 a.m. ET. Learn more today!","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021 | BridgeBio","og_description":"BridgeBio announced that it will host its second R&D Day on Tuesday, October 12, 2021, at 8:30 a.m. ET. Learn more today!","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/","og_site_name":"BridgeBio","article_published_time":"2021-10-06T19:00:00+00:00","article_modified_time":"2022-06-23T15:41:01+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Cybele Gouverneur","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Cybele Gouverneur","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/","name":"BridgeBio Pharma to Host Virtual R&D Day on October 12, 2021 | BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2021-10-06T19:00:00+00:00","dateModified":"2022-06-23T15:41:01+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7"},"description":"BridgeBio announced that it will host its second R&D Day on Tuesday, October 12, 2021, at 8:30 a.m. ET. Learn more today!","breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-pharma-to-host-virtual-rd-day-on-october-12-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma to Host Virtual R&#038;D Day on October 12, 2021"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/0ccd4f21aad52916b60d0206bb498df7","name":"Cybele Gouverneur","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1310df87abb2898678c7deb92afe7bc4?s=96&d=mm&r=g","caption":"Cybele Gouverneur"},"url":"https:\/\/bridgebio.com\/author\/cybele-gouverneur\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5211"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=5211"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5211\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=5211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=5211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=5211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}